Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs
Open Access
- 1 November 2023
- journal article
- editorial
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 14 (6) , 879-884
Abstract
Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy ...Keywords
This publication has 10 references indexed in Scilit:
- A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Beta-interferon I-a Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran2019
- A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosisNeurological Sciences, 2018
- Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta2014
- The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurology, 2011
- Adverse Events of Interferon Beta-1a: A Prospective Multi-Centre International ICH-GCP-Based CRO-Supported External Validation Study in Daily PracticePLOS ONE, 2011
- Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.2008
- Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head studyActa Neurologica Scandinavica, 2006
- A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MSNeurology, 2002
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Focusing on the preventability of adverse drug reactions.1992